Industry / Poland
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Polpharma To Buy 33.3% Stake In Bioton
August 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Poland's leading domestic drugmaker, Polpharma, is to buy a 33.3% stake in Bioton for an initial PLN450mn (US$198.9mn), the biotechnology company said on August 15 2008. The deal could increase in value by an additional PLN50mn (US$22.1mn) if a future interferon-based drug gains European Medicines Agency (EMEA) approval. Jerzy Starak, owner of Polpharma, described the deal as a 'portfolio investment' rather than a 'strategic investment', and said that while there may be some co-operation between the firms in future, this was not currently on the